{"filing":{"accession_number":"0001171843-26-006273","cik":"0001677940","ticker":"BYSI","company_name":"BeyondSpring Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"f8k_092826.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1677940/000117184326006273/f8k_092826.htm"},"events":[{"id":35580,"run_id":32779,"accession_number":"0001171843-26-006273","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.9,"summary":"BeyondSpring entered into a Share Purchase and Collaboration Agreement on September 28, 2026, to sell its entire equity interest in BeyondSpring Ltd. (which indirectly holds majority interest in its Chinese subsidiary Bulin) to Biolin Investment Limited. The buyer will provide non-cash consideration through funding of the China portion of the Phase 3 DUBLIN-4 trial, substantially reducing BeyondSpring's cash requirements while advancing a critical clinical milestone.","company_name":"BeyondSpring Inc.","ticker":"BYSI","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39674,"accession_number":"0001171843-26-006273","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"BeyondSpring entered into a Share Purchase and Collaboration Agreement on September 28, 2026, to sell its entire equity interest in BeyondSpring Ltd. (which indirectly holds majority interest in its Chinese subsidiary Bulin) to Biolin Investment Limited. This constitutes a material disposition of a subsidiary. Although structured as a non-cash transaction with the buyer's obligation to fund the China portion of the DUBLIN-4 trial serving as consideration, it represents a fundamental change in ownership and control of a material asset—the company's Chinese operations—and is disclosed under Item 1.01 as a material definitive agreement. The press release emphasizes this as a \"strategic transaction\" expected to \"substantially reduce BeyondSpring's cash requirements\" for its Phase 3 trial, confirming materiality to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:04:41.844706+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39675,"accession_number":"0001171843-26-006273","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"BeyondSpring announced a strategic transaction to sell its majority equity interest in its Chinese subsidiary (Bulin) to Biolin Investment Limited. This constitutes a material disposition of a subsidiary, with Biolin providing non-cash consideration through funding of the China portion of the Phase 3 DUBLIN-4 trial (approximately 50% of the 442-patient global enrollment). The transaction is expected to substantially reduce BeyondSpring's cash requirements while advancing a critical clinical milestone, making it a material capital event affecting the registrant's financial position and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:04:41.844706+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39674,"accession_number":"0001171843-26-006273","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"BeyondSpring entered into a Share Purchase and Collaboration Agreement on September 28, 2026, to sell its entire equity interest in BeyondSpring Ltd. (which indirectly holds majority interest in its Chinese subsidiary Bulin) to Biolin Investment Limited. This constitutes a material disposition of a subsidiary. Although structured as a non-cash transaction with the buyer's obligation to fund the China portion of the DUBLIN-4 trial serving as consideration, it represents a fundamental change in ownership and control of a material asset—the company's Chinese operations—and is disclosed under Item 1.01 as a material definitive agreement. The press release emphasizes this as a \"strategic transaction\" expected to \"substantially reduce BeyondSpring's cash requirements\" for its Phase 3 trial, confirming materiality to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:04:41.844706+00:00","company_name":"BeyondSpring Inc.","ticker":"BYSI","filing_date":"2026-09-29"},{"id":39675,"accession_number":"0001171843-26-006273","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"BeyondSpring announced a strategic transaction to sell its majority equity interest in its Chinese subsidiary (Bulin) to Biolin Investment Limited. This constitutes a material disposition of a subsidiary, with Biolin providing non-cash consideration through funding of the China portion of the Phase 3 DUBLIN-4 trial (approximately 50% of the 442-patient global enrollment). The transaction is expected to substantially reduce BeyondSpring's cash requirements while advancing a critical clinical milestone, making it a material capital event affecting the registrant's financial position and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:04:41.844706+00:00","company_name":"BeyondSpring Inc.","ticker":"BYSI","filing_date":"2026-09-29"}]}